Eli Lilly’s Omvoh (mirikizumab-mrkz) has shown continued benefit after four years in a Phase III open-label extension trial ...

(Reuters) -Eli Lilly has halted a study of an experimental drug, designed to prevent obesity patients from losing too much ...

Eli Lilly continues to establish its dominance in the growing market for GLP-1 therapies. The company's oral candidate for ...

Eli Lilly's Omvoh shows long-term remission and improved quality of life for ulcerative colitis patients in new trial results ...

If you have been keeping an eye on Eli Lilly’s stock, you are not alone, and you are probably wondering if now is the right ...

The clinical trial that Eli Lilly terminated was expected to enroll 180 people and finish in late 2026. The trial had been measuring how well Bimagrumab stimulates weight loss and preserves muscle ...

Eli Lilly (NYSE: LLY) recently released top-line results from a head-to-head trial of its oral GLP-1 pill, orforglipron, compared to Novo Nordisk's (NYSE: NVO) oral version of Weg ...

Detailed price information for Eli Lilly and Company (LLY-N) from The Globe and Mail including charting and trades.

Eli Lilly & Co. halted a study of an experimental drug designed to prevent obesity patients from losing too much muscle, citing strategic business reasons it didn’t disclose.

Though Eli Lilly has shelved the obesity and T2D trial involving Zepbound, the US pharma will continue its obesity-only trial ...

Eli Lilly said on Thursday the U.S. Food and Drug Administration has approved its treatment for a form of advanced breast ...

US pharma major Eli Lilly has halted a study of an experimental drug, bimagrumab, designed to prevent obesity patients from ...